Fig. 4From: Defective migration and dysmorphology of neutrophil granulocytes in atypical chronic myeloid leukemia treated with ruxolitinibRuxolitinib therapy causes loss of CSF3R mutated clone, cell size normalization, but only marginally compensates the migration defect of aCML neutrophils. a Variant allele frequency (VAF) of candidate genes of the aCML patient over the course of ruxolitinib therapy. b Changes in the migratory patterns, percentage of moving cells (left) and speed excluding non-moving cells (speed excl. Nmc., right), of the aCML neutrophils over the course of treatment. From top to bottom, cells were stimulated with PBS, fMLP [10 nM], CXCL1 [100 ng/ml] and CXCL8 [100 ng/ml]. Black triangles and black solid lines indicate aCML neutrophils (every timepoint n = 1), while grey dots and grey dashed lines indicate the median and the grey dotted lines indicate the interquartile range of the age- and gender-matched controls (n = 6). Numbers label the specific values of aCML neutrophils reached for percentage of moving cells (left) and speed excluding non-moving cells (right) respectively. c Changes in cell size of aCML neutrophils under the four different stimulation conditions over the course of therapy. Black triangles and black solid lines indicate aCML neutrophils (every timepoint n = 1), while grey dots and grey dashed lines indicate the median and the grey dotted lines indicate the interquartile range of the age- and gender-matched controls (n = 6). On average, 41 and 56 cells per condition were analyzed in age- and gender-matched controls and the aCML patient, respectively. Numbers label the specific cell sizes as the mean cell size of all cellsBack to article page